Vitamin D3

Quick links to important sections

Vitamin D3

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vitamin D3

Property Description
Active Ingredient Dihydrotachysterol (DHT)
Pharmacological Class Synthetic Vitamin D Analogue, Antihypocalcemic Agent
Forms Oral solution, capsule, tablet
Origin Synthetic, Vitamin D2 derivative
General Purpose Regulating blood calcium and phosphate levels

What Type of Medicine is Dihydrotachysterol?

Dihydrotachysterol (DHT) is a synthetic medicinal compound classified as a Vitamin D analogue and an antihypocalcemic agent. The active ingredient, Dihydrotachysterol, is a modified sterol derived from Vitamin D2 (Ergocalciferol), functioning as a pro-hormone that the body converts into a biologically active form. Dihydrotachysterol is characterized by a rapid onset of action and reduced dependence on kidney enzymes for activation compared to natural forms of Vitamin D. This structural difference is clinically recognized for providing a unique mechanism in mineral management.

Composition, Origin, and Available Forms

Dihydrotachysterol is a synthetic, single-ingredient compound that is manufactured rather than derived directly from natural sources. This compound is administered orally and is available in several forms, including a capsule, tablet, and oral solution.

As a single-ingredient product, its entire therapeutic effect comes solely from the Dihydrotachysterol molecule. For instance, the liquid oral forms typically utilize an oil or alcoholic base to ensure stability and aid in effective absorption through the digestive tract. This formulation specificity is a differentiating factor, as it allows for precise control of the delivered compound.

What is the General Purpose of This Vitamin D Analogue?

The general purpose of Dihydrotachysterol is to act as a calcemic agent to actively regulate and elevate the concentrations of calcium and phosphate in the blood. The primary role of this class of compounds is to manage mineral homeostasis vital for normal nerve and muscle function. This function is essential in a typical use scenario where an individual may have compromised natural Vitamin D metabolism, supporting overall physiological stability.

What side effects are possible with Vitamin D3?

Possible Side Effects and Safety Information

The official safety profile for Dihydrotachysterol, a synthetic Vitamin D analogue, is predominantly defined by its effects on mineral balance, which can lead to hypercalcemia (elevated calcium in the blood) and hypercalciuria (elevated calcium in the urine). These adverse reactions are typically classified as uncommon in regulatory documents.


System-Organ Classes and Common Manifestations

Adverse effects are documented across several system-organ classes, mainly as consequences of hypercalcemia. These include Gastrointestinal disorders (such as nausea, vomiting, constipation, and abdominal pain), Nervous system disorders (including fatigue, confusion, and vertigo), and Skin and subcutaneous tissue disorders related to uncommon hypersensitivity reactions (pruritus, rash, and urticaria).


Serious Adverse Reactions and Duration-Related Risks

Severe or uncontrolled hypercalcemia is associated with documented serious adverse outcomes, particularly involving the kidneys. These include nephrocalcinosis (calcification of the renal tissue) and the risk of irreversible renal insufficiency. Regulatory safety notes indicate that the pharmacological effects of the medicine may persist for two or more months after treatment is discontinued, and uncontrolled prolonged use carries the risk of nephrocalcinosis.


Population-Specific Safety Considerations

Specific safety statements are provided for use during pregnancy and lactation. Official labeling notes the potential for foetal damage if used during pregnancy and the risk of hypercalcemia in the newborn. Additionally, the medicine is known to be excreted in breast milk and may cause hypercalcemia in the suckling infant.

Use is formally contraindicated in patients with pre-existing Hypercalcaemia or Hypervitaminosis D.

Overdose and Emergency Response

The official regulatory profile for the Vitamin D analogue Dihydrotachysterol overdose is centered on the resulting condition of Hypercalcaemia, or Hypervitaminosis D, which causes all documented manifestations and serious outcomes.

Property Official Regulatory Statement
Documented Overdose Presentations Early signs include anorexia, nausea, vomiting, headache, weakness, and excessive thirst or urination. Key laboratory findings include hypercalciuria and reversible azotemia.
Severe/Life-Threatening Outcomes Severe hypercalcaemia can lead to complications such as cardiac arrhythmias, hypertension, vascular calcification, and renal insufficiency (nephrocalcinosis). Seizures and coma are also documented.
When Immediate Medical Help is Required Get medical help or contact a Poison Control Center right away in case of suspected overdose. Severe hypercalcaemia is considered a medical emergency requiring immediate attention and hospitalization.

Official overdose statements:

  • Overdose mandates the immediate withdrawal of Dihydrotachysterol and any supplemental calcium.
  • Treatment is symptomatic and supportive, aiming to correct the underlying hypercalcaemia through measures such as fluid administration and institution of a low-calcium diet. No specific antidote is known.
  • Serum calcium levels must be closely monitored until they return to the normal range.

Regulatory documents explicitly define the overdose profile by the systemic consequences of severe Hypercalcaemia, which directly causes the documented severe outcomes. This risk mandates that individuals seek immediate medical attention to address the toxicity and prevent irreversible complications, such as renal damage.

Therapeutic Uses of Vitamin D3

Quick Facts

  • Rickets: Helps manage the risk of rickets in children, a condition involving soft and weak bones.
  • Osteomalacia: May address the softening of bones in adults (osteomalacia) associated with severe deficiency.
  • Bone Health: Supports the body in utilizing calcium, which contributes to the maintenance of normal bones.

What Vitamin D3 Treats: Main Uses and Benefits

Vitamin D3 (cholecalciferol) supports several vital bodily processes. A primary function is to support calcium absorption in the gut. This action helps the body maintain adequate serum calcium and phosphate levels, which is a key component for the maintenance of normal bone and muscle function.

Vitamin D may be used to prevent and address states of deficiency that can affect the health of the skeleton. In children, maintaining adequate status may help manage the risk of developing rickets, a condition characterized by bone weakening and malformation. In adults, deficiency is associated with osteomalacia (bone softening), and addressing low status may help reduce the risk of this condition.

For older adults, taking Vitamin D along with calcium may contribute to reducing bone mineral loss, which may help in the management of osteoporosis.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Who Can and Cannot Use Vitamin D3 (Cholecalciferol)

The eligibility for Vitamin D3 (Cholecalciferol) is strictly defined by regulatory authorities based on established contraindications and population restrictions.

Absolute Contraindications (Must Not Use): Use of Cholecalciferol is strictly prohibited in individuals diagnosed with hypercalcemia (high blood calcium levels) or hypervitaminosis D (excessive vitamin D levels in the body). It is also contraindicated for patients with a known hypersensitivity to the drug or any of its components.

Populations Requiring Conditional Use: The medicine is generally established for use in adults and pediatric patients. However, use requires careful supervision for individuals with severe renal insufficiency or malabsorption syndromes, as these conditions can affect the compound's metabolism or absorption. Patients with certain conditions like sarcoidosis or hyperparathyroidism also require close medical monitoring.

Age and Physiological State Limitations: While approved across the lifespan, some high-strength products are officially not recommended for use in children and adolescents under 18 years due to insufficient data. Use during pregnancy and breastfeeding is permitted, but official labels mandate avoiding high doses and require specific medical consultation regarding appropriate dosage needs.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for this Vitamin D analogue (Dihydrotachysterol) is characterized by pharmacokinetic and pharmacodynamic risks, as defined by official regulatory documentation.


Interaction-Related Restrictions Co-administration with other Vitamin D Analogs or pharmacologic doses of Vitamin D is restricted due to the significant risk of additive effects, including hypercalcemia and hyperphosphatemia.

Clinically Significant Official Statements

  • Thiazide Diuretics increase the risk or severity of hypercalcemia due to reduced renal excretion of calcium.
  • Cardiac Glycosides (e.g., Digoxin) increase the risk of ventricular arrhythmias due to Dihydrotachysterol’s effect on serum calcium levels.
  • Anticonvulsants (e.g., Phenytoin) may reduce therapeutic efficacy through accelerated metabolism in the liver.
  • Bile Acid Sequestrants (e.g., Cholestyramine) decrease the serum concentration by reducing absorption.
  • Aluminum-containing antacids increase the risk of aluminum absorption and retention.
  • Grapefruit or grapefruit juice may alter product blood levels.

Population-Specific Notes Patients with renal or hepatic dysfunction may have an altered drug response, which can exacerbate interaction outcomes and toxicity.


The overall interaction structure is defined by the Pharmacodynamic Risk of Hypercalcemia, which dictates restrictions with agents that also increase serum calcium, and Exposure Modification, which accounts for altered drug levels due to metabolic pathways and absorption interference.

Mechanism of Action

Vitamin D3, or cholecalciferol, must first undergo two sequential hydroxylation steps, primarily in the liver and kidneys, to form its active metabolite, calcitriol (1,25-dihydroxyvitamin D3). Calcitriol acts as a high-affinity agonist for the nuclear Vitamin D Receptor (VDR), which is expressed in cells of the intestine, bone, kidney, and parathyroid gland. The VDR/calcitriol complex functions as a transcription factor, modulating the expression of numerous target genes, which include those responsible for calcium transport proteins. The most notable downstream cascade is the VDR-mediated increased intestinal absorption of calcium and phosphate, which influences serum mineral homeostasis. Furthermore, calcitriol directly acts on osteoblasts to modulate the regulated process of bone mineralization and directly inhibits the secretion of Parathyroid Hormone (PTH). This integrated action influences the balance of bone formation and resorption and affects cell function in musculoskeletal tissues.

Dosage and Administration Information

How Dihydrotachysterol (DHT) is Used

The usage of Dihydrotachysterol (DHT), a synthetic Vitamin D analogue, is characterized by a formal, two-phase treatment protocol for managing mineral levels in conditions like hypoparathyroidism. The sole approved route of administration is oral, available in capsule, tablet, and oral solution forms.

Official Administration Protocol

Therapy begins with a short-term initial loading dose to rapidly adjust mineral concentrations. For adults, this phase typically involves a higher dose, such as 0.8 mg to 2.4 mg once daily, lasting for a few days. This is followed by a lower, long-term maintenance dose, generally ranging from 0.2 mg to 1.0 mg once daily.

Use Conditions and Frequency

Administration is conditional on specific co-treatment and monitoring requirements. In this regimen, DHT is taken concomitantly with adequate calcium supplementation. Dosing occurs once daily, but adjustments to the maintenance amount are made cautiously at long intervals, such as four to eight weeks, due to the drug’s extended pharmacological duration. Adjustments are guided by frequent monitoring of serum calcium levels, which are maintained within a designated target range.

Population-Specific Use

Specific dosing regimens are defined for pediatric patients (infants and children), differing from adult guidelines for both initial and maintenance phases. For patients with renal impairment, this analogue is often utilized because it does not rely on kidney enzymes for its final activation, simplifying its metabolic pathway compared to non-activated forms of Vitamin D.

Recent Clinical Evidence

Research evidence / Overview of studies for Cholecalciferol (Vitamin D3)


Evidence for use in Correcting Deficiency and Established Bone Conditions

Research has long explored the association between Vitamin D3 status and mineral homeostasis. The early evidence base for research examining low Vitamin D status and the study of diseases like rickets in children and osteomalacia in adults is part of the foundational research landscape. These findings describe patterns observed in the studies of individuals with documented severe deficiency. Researchers primarily used observational studies and systematic reviews to examine the relationship between low status and the development of these bone disorders.

Findings indicate that the administration of Vitamin D3 was associated with increases in measured 25(OH)D levels, and changes in calcium and phosphate levels were also observed. Clinical descriptions reported how symptoms evolved in the observed populations, noting changes aligned with the resolution of rickets and osteomalacia. While the foundational research related to this is extensive, certainty remains low regarding the optimal target level of 25(OH)D needed to observe the greatest health change for all individuals.


Evidence for use in Bone Health and Fracture Prevention

This area of research explored how Vitamin D3 was evaluated in studies focusing on skeletal endpoints and fracture incidence rates, particularly in older adults. The evidence mainly comes from large-scale, long-term Randomized Controlled Trials (RCTs). Studies monitored outcomes related to Bone Mineral Density (BMD) and the incidence rate of fractures.

Findings were mixed across the total body of research. Some trial sub-group analyses described patterns observed in the studies related to fracture incidence, primarily in populations with very low baseline Vitamin D levels. Many large trials reported only modest or non-significant changes in BMD when compared to control groups. These patterns highlight that for skeletal outcomes in general community-dwelling populations, the evidence is not as consistent.

What remains uncertain is whether research supports the evaluation of Vitamin D3 alone, or if skeletal outcomes observed may depend on the co-administration of calcium. The evidence quality varies across studies, meaning that the certainty level for skeletal outcomes in the general population is considered limited.


What is Still Uncertain About Vitamin D3 Research

A primary limitation is the variability in findings across studies, especially for non-skeletal outcomes. For instance, the findings were mixed regarding the study outcomes related to muscle strength measurements or fall frequency. Furthermore, comparative evidence is lacking regarding the varying dosing regimens used in studies and how these differing approaches affect long-term safety and outcomes. Subgroup findings are uncertain, underscoring the need for ongoing research to provide insight into short-term changes in a more consistent manner.

Frequently Asked Questions (FAQ)

Common questions about Vitamin D3 (FAQ)

Q: What is the difference between Vitamin D and Vitamin D3?

A: Vitamin D is the collective name for a group of fat-soluble vitamins. The two main forms are Vitamin D2 (Ergocalciferol) and Vitamin D3 (Cholecalciferol). Official information from health authorities, such as the NIH, notes that D3 is the form naturally synthesized in the skin when exposed to sunlight, making it a widely available and commonly used supplemental form.

Q: Why is Vitamin D3 often called the 'sunshine vitamin'?

A: Vitamin D3 earned this nickname because the body can produce it endogenously. This occurs when ultraviolet (UV) B rays from sunlight contact the skin, initiating the process of Vitamin D3 synthesis.

Q: Does Vitamin D3 support the immune system?

A: Regulatory information from sources like DailyMed indicates that Vitamin D is involved in maintaining several biological functions beyond just bone health. Specifically, it is noted for its role in modulating neuromuscular and immune function.

Q: Can taking Vitamin D3 cause stomach upset?

A: Adverse effects related to the gastrointestinal system, such as nausea, vomiting, and stomach pain, are generally associated with hypercalcemia (abnormally high calcium levels). Hypercalcemia is a key symptom of Vitamin D toxicity, which occurs with excessive intake, not typically with standard supplemental doses.

Q: Does Vitamin D3 interact with blood pressure medication?

A: Yes, official drug safety data warns of a potential interaction with a class of blood pressure medications called Thiazide diuretics. Taking Vitamin D concurrently with these drugs can increase the risk of developing hypercalcemia (high calcium levels) because they reduce the kidney's excretion of calcium.

Q: Should Vitamin D3 be taken with a meal?

A: Official prescribing information for some products advises taking Vitamin D3 with food. Vitamin D is a fat-soluble vitamin, and regulatory information indicates absorption may be enhanced when the supplement is taken with food.

Q: Do statins affect Vitamin D3 levels or absorption?

A: Drug interaction information suggests that both statins (like Atorvastatin) and Vitamin D are processed by the same liver enzyme system (CYP3A4). The simultaneous metabolism by the same liver enzyme system suggests a potential for altered drug levels, and this should be considered against specific regulatory guidance.

Q: Is Vitamin D3 safe for people with kidney stones?

A: Official regulatory documents generally state that Vitamin D3 is contraindicated (must not be used) in patients with a history of nephrolithiasis (kidney stones) or a tendency to form calcium-containing kidney stones. This is related to the known risk of increased calcium levels (hypercalcemia) potentially affecting individuals with this condition.

Q: Is it normal to feel tired when first starting Vitamin D3?

A: Fatigue or tiredness is officially listed as a symptom associated with hypercalcemia, which is a sign of Vitamin D toxicity (overdose). It is not typically cited as a common side effect of initiating standard supplementation.

Q: What is the difference between Vitamin D2 and D3, and which is better absorbed?

A: The two main supplemental forms are D2 (Ergocalciferol), derived from plants and yeast, and D3 (Cholecalciferol), synthesized in the skin or derived from animal sources. D3 is the form often noted as being more effective at raising and sustaining blood levels of Vitamin D.

Q: What foods are naturally high in Vitamin D3?

A: According to official nutritional guidelines, the best natural food sources of Vitamin D3 include fatty fish (like salmon and mackerel), fish liver oils, and amounts found in egg yolks.

Q: Are there vegetarian or vegan sources of Vitamin D3 supplements?

A: It is important to check the product formulation, as many Vitamin D3 supplements are derived from animal sources like lanolin or use animal-based gelatin for capsules. Plant-derived D3, such as that sourced from lichens, is available for vegetarian and vegan diets.

Q: Why is Vitamin D3 important for muscle function?

A: Official regulatory monographs highlight that Vitamin D is essential for regulating neuromuscular function. This means it plays a fundamental role in the communication between the nerves and muscles.

Q: Does Vitamin D3 play a role in heart health?

A: While Vitamin D is not a primary cardiac medication, regulatory warnings indicate its connection to heart function. Specifically, caution is advised for patients with heart conditions or those taking drugs like cardiac glycosides (e.g., Digoxin), as elevated calcium levels can affect the heart's rhythm.

Q: What are the possible signs of Vitamin D3 toxicity?

A: Official prescribing information describes symptoms of an overdose (Hypervitaminosis D). Early signs may include general symptoms like weakness, metallic taste, weight loss, bone pain, and stomach issues such as nausea, vomiting, and constipation.

Q: How is Vitamin D3 level measured in a blood test?

A: The level of Vitamin D status is commonly assessed by measuring the concentration of 25-hydroxyvitamin D [25(OH)D] in the blood serum, according to the NIH and other health authorities.

Q: Does Vitamin D3 affect hormone balance?

A: Yes, regulatory and scientific sources note that the active form of Vitamin D acts as a hormone. It binds to the Vitamin D Receptor (VDR), which belongs to the nuclear receptor superfamily of steroid hormones.

Q: Why is Vitamin D3 important during the winter months?

A: In many northern latitudes, the sun's angle during the winter months makes it difficult or impossible for the skin to effectively synthesize Vitamin D3. Health authorities emphasize the importance of supplementation or dietary sources during this time.

Q: Is it true that Vitamin D3 needs fat to be properly absorbed?

A: Yes, Vitamin D is categorized as a fat-soluble vitamin. Official product labels and health resources confirm that the absorption of the supplement may be enhanced by concurrent fat consumption.

Q: Does Vitamin D3 interact with corticosteroids?

A: Yes, drug interaction information indicates that taking glucocorticoids (a type of corticosteroid) can potentially decrease the overall therapeutic effect of Vitamin D in the body.

Q: Is there research on Vitamin D3 and autoimmune diseases?

A: Official health agency research summaries confirm that studies have explored the potential connection between Vitamin D deficiency and various inflammatory and autoimmune health conditions.

Q: Are there any common side effects from high-dose Vitamin D3?

A: High doses carry the primary risk of hypercalcemia (excessive calcium in the blood), which is the source of most adverse reactions. Regulatory information specifies that symptoms can include increased thirst, frequent urination, nausea, and vomiting.

Q: Can children take Vitamin D3 supplements?

A: Official regulatory documents confirm that Vitamin D3 is generally established for use in the pediatric population. However, labeling often warns that high-strength products are not recommended for infants and young children due to an increased risk of toxicity.

Q: Can I take Vitamin D3 if I am already taking a multivitamin?

A: Official warnings from regulatory bodies recommend accounting for all sources of Vitamin D, including any contained in a multivitamin or fortified foods. This caution is advised to prevent total daily intake from becoming excessive and causing a risk of hypervitaminosis D.

Q: Is it safe to take Vitamin D3 while breastfeeding?

A: Use during breastfeeding is generally allowed but requires medical guidance. Official labeling cautions that high doses should be avoided because Vitamin D is excreted in breast milk and high levels could potentially cause hypercalcemia (high calcium) in the nursing infant.

Q: Can I take Vitamin D3 with antacids?

A: Interaction warnings focus particularly on aluminum-containing antacids. Vitamin D can increase the body's absorption of aluminum. This caution is especially relevant for patients with compromised kidney function. Separating the administration times of these two products may be recommended.

Q: Can certain weight loss drugs interfere with Vitamin D3 absorption?

A: Yes, regulatory data indicates that certain medications, such as Bile Acid Sequestrants and Orlistat, can interfere with the body's ability to absorb fat-soluble vitamins, including Vitamin D. Separating the dosing of the two medications is often recommended.

How should Vitamin D3 be stored and disposed of?

How to Store and Dispose of Vitamin D3

Storage and disposal of Vitamin D3 (cholecalciferol) must strictly follow the conditions specified in official regulatory labeling to maintain potency and stability.


Storage Requirements

Item Official Regulatory Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Must be protected from light and moisture.
Container Keep the medicine in the original container and tightly closed.
Prohibition Do not freeze the product.
Safety Store out of the reach and sight of children.

Disposal Instructions

Unused or expired Vitamin D3 must be disposed of according to local regulations for pharmaceutical waste. The product must not be disposed of via wastewater (such as flushing down the toilet) or placed in household trash, unless local rules specifically permit it. Consult a pharmacist for guidance on medicine take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vitamin D3 found in:

A-Z Index: